Centre Hospitalier Universitaire de Liège (CHU Liège)

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease (2025) Jessen F, Arbizu J, Boada M, Balasa M, Bennys K, Boban M, Bürger K, et al. Journal article Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study (2025) Noviello D, Chaparro M, Viganò C, Blesl A, Barberio B, Yanai H, Orlando A, et al. Journal article Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials (2024) Peyrin‐Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola , Jahnsen J, et al. Journal article ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment (2024) Adamina M, Minozzi S, Warusavitarne J, Buskens CJ, Chaparro M, Verstockt B, Kopylov U, et al. Journal article Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials (2024) Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, et al. Journal article Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire (2024) Halimi JM, Sarafidis P, Azizi M, Bilo G, Burkard T, Bursztyn M, Camafort M, et al. Journal article Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R (2024) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, et al. Journal article ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. (2024) Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, et al. Journal article Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure (2024) Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article